# A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

> **NCT05462873** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Esophageal Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **BIOLOGICAL:** QEQ278

## Key facts

- **NCT ID:** NCT05462873
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-04
- **Primary completion:** 2026-01-26
- **Final completion:** 2026-01-26
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Business decision and not related to safety concerns
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462873, "A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT05462873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*